Haemonetics (HAE) Tops Q3 EPS by 10c; raises guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $72.53 -2.21%
EPS Growth %: -0.9%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -0.9%
Financial Fact:
Selling, general and administrative: 71.12M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q3 EPS of $1.04, $0.10 better than the analyst estimate of $0.94. Revenue for the quarter came in at $336 million versus the consensus estimate of $320.77 million.
GUIDANCE:
Haemonetics sees FY2024 EPS of $3.90-$4.00, versus the consensus of $3.89.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- AeroVironment restates quarterly financials, citing $89M goodwill error
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
